Citi raises Microsoft stock price target to $613 on strong Azure growth

Published 22/07/2025, 12:24
© Reuters.

Investing.com - Citi has raised its price target on Microsoft (NASDAQ:MSFT) stock to $613.00 from $605.00 while maintaining a Buy rating, citing expectations of strong quarterly results and positive revisions. The stock, currently trading at $510.06 and near its 52-week high of $514.64, has delivered a 21.48% return year-to-date. According to InvestingPro analysis, Microsoft’s current valuation metrics suggest the stock is trading at premium multiples.

The firm anticipates "another strong quarter of positive revisions and upside to Q4+Q1 Azure numbers" for Microsoft’s fiscal fourth quarter results. Citi’s reseller survey showed one of the strongest growth and quota attainment performances in over four years.

Partner checks highlighted strength in Microsoft’s CoPilot and Dynamics offerings, according to the research note. After previously raising Azure estimates in mid-June, Citi has further increased its projections.

Citi’s fiscal year 2026 estimate for Azure growth remains approximately three percentage points above the broader market consensus. The new price target is based on 30 times fiscal year 2028 earnings per share discounted back.

Microsoft remains Citi’s top pick in the sector due to its AI exposure, business model quality, and long-term pricing and margin power that the firm views as "nearly unmatched in enterprise software."

In other recent news, Microsoft has been the focus of several analyst updates and strategic developments. RBC Capital reiterated its Outperform rating on Microsoft, citing healthy cloud conditions and phased rollouts of its Copilot feature across enterprise clients. Additionally, BofA Securities raised its price target for Microsoft to $585, reflecting confidence in the company’s Azure cloud services, and noted the potential for a slight revenue increase in the upcoming fourth-quarter results. Meanwhile, OpenAI has entered into a strategic partnership with the UK government to accelerate AI adoption, focusing on economic and societal benefits through AI in public and private sectors.

In related news, Tevogen Bio announced the publication of its international patent application for AI-powered peptide prediction technology, developed in collaboration with Microsoft and Databricks. The World Intellectual Property Organization published this patent, highlighting Tevogen’s use of machine learning to predict immunologically active peptides. Furthermore, U.S. lawmakers have raised concerns with major tech companies, including Microsoft, about the security of submarine communications cables potentially serviced by Chinese and Russian entities. These developments underscore the dynamic landscape of technological advancements and regulatory scrutiny in the industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.